Tiefenbacher API+ Ingredients Offers Custom Synthesis Of Intermediates & Apis
Tiefenbacher Group welcome our new COO for AET Laboratories, Sandip Tarate
Tiefenbacher Group awarded the EcoVadis Silver Medal!
Tiefenbacher Pharmaceuticals Launch Of Generic Teriflunomide
Successful Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority
As the allergy season is starting, we at TIEFENBACHER PHARMACEUTICALS are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany.
We are excited to announce that our two manufacturing sites at AET Laboratories in Hyderabad (India) and at Delorbis in Lefkosia (Cyprus) have been successfully registered by the United Arab Emirates Ministry of Health! The approvals are based on our existing European and international certifications and follow Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada.
Four drugs recommended for approval by CHMP at April meeting
Tiefenbacher API + Ingredients Secures The Supply Of Controlled Substances For Customers And Patients